lifestyle.floredechampagne.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Maze Therapeutics, Inc.
Maze Therapeutics Announces $150 Million Registered Offering
April 22, 2026
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
March 25, 2026
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
March 25, 2026
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
February 25, 2026
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026